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Abstract
Background: While Candida pneumonia is life-threatening, biomarker measurements to early detect suspected
Candida pneumonia are lacking. This study compared the diagnostic values of measuring levels of (1, 3)-β-D-
glucan in endotracheal aspirate, bronchoalveolar lavage fluid, and serum to detect suspected Candida
pneumonia in immunocompromised and critically ill patients.
Methods: This prospective, observational study enrolled immunocompromised, critically ill, and ventilated patients
with suspected fungal pneumonia in mixed intensive care units from November 2010 to October 2011. Patients with
D-glucan confounding factors or other fungal infection were excluded. Endotracheal aspirate, bronchoalveolar lavage
fluid and serum were collected from each patient to perform a fungal smear, culture, and D-glucan assay.
Results: After screening 166 patients, 31 patients completed the study and were categorized into non-Candida
pneumonia/non-candidemia (n = 18), suspected Candida pneumonia (n = 9), and non-Candida pneumonia/candidemia
groups (n = 4). D-glucan levels in endotracheal aspirate or bronchoalveolar lavage were highest in suspected Candida
pneumonia, while the serum D-glucan level was highest in non-Candida pneumonia/candidemia. In all patients, the
D-glucan value in endotracheal aspirate was positively correlated with that in bronchoalveolar lavage fluid. For the
detection of suspected Candida pneumonia, the predictive performance (sensitivity/specificity/D-glucan cutoff [pg/ml]) of
D-glucan in endotracheal aspirate and bronchoalveolar lavage fluid was 67%/82%/120 and 89%/86%/130, respectively,
accounting for areas under the receiver operating characteristic curve of 0.833 and 0.939 (both P < 0.05), respectively.
Measuring serum D-glucan was of no diagnostic value (area under curve =0.510, P = 0.931) for the detection of
suspected Candida pneumonia in the absence of concurrent candidemia.
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Conclusions: D-glucan levels in both endotracheal aspirate and bronchoalveolar lavage, but not in serum, provide good
diagnostic values to detect suspected Candida pneumonia and to serve as potential biomarkers for early detection in this
patient population.
Keywords: (1,3)-β-D-glucan, Bronchoalveolar lavage, Candida pneumonia, Critically ill patients, Diagnosis,
Intensive care unit
Background
Candida pneumonia (CP) is life-threatening and has been
associated with a high attributable mortality [1]. However,
the definitive diagnosis is rarely established before over-
whelming sepsis or death. Conventionally, a lung biopsy has
been proposed to confirm CP [2, 3], but the procedure is
too risky for patients in intensive care units (ICUs) because
of the high prevalence of thrombocytopenia and coagulopa-
thy [4]. Growth of respiratory Candida spp. in immuno-
compromised, cancer-afflicted, and critically ill patients is
frequently found, but it is usually considered colonization
rather than CP [5]. Indeed, growth of respiratory Candida
spp. lacks specificity to diagnose CP [6–9], and adds little
value to optimizing CP management [10, 11]. Recently,
growing evidence has challenged the dogma that respiratory
Candida spp. acts as a bystander in ICU patients [12]. The
presence of respiratory Candida spp. has been shown to be
associated with increased bacterial pneumonia development
[13–16], selection of multidrug-resistant bacteria [17], and
worse ICU outcomes [14, 18–20]. Accordingly, measure-
ments of biomarkers with diagnostic value for the early de-
tection of suspected CP are urgently needed.
Measurements of serum (1,3)-β-D-glucan (BDG), the
common fungal wall antigen, can now be accomplished
within hours. Measuring serum BDG has emerged as a
rapid assessment to facilitate the diagnosis of invasive
fungal infection, and it has proven to provide indirect
mycological evidence for invasive fungal infection by a
task force consensus [3]. A recent meta-analysis of 2979
patients included from 16 studies showed that using
serum BDG levels to diagnose invasive fungal infection
could attain a pooled sensitivity and specificity of 76.8
and 85.3%, respectively, and an area under the receiver
operating characteristic curve (AUROC) of 0.89 [20].
However, none of these studies focused on respiratory
Candida spp. infection. Additionally, it is conceivable
that measuring BDG levels in respiratory specimens
might be more accurate and specific for the diagnosis of
pulmonary infection compared to measuring BDG levels
in serum. Thus, the diagnostic value of measuring BDG
levels in serum or respiratory specimens to detect sus-
pected CP remains unclear.
In this study, we conducted a prospective, observa-
tional study aiming to compare the diagnostic value of
measuring BDG levels in endotracheal aspirate (TA),
bronchoalveolar lavage (BAL) fluid, and serum for the




This prospective, observational study was conducted at
medical and surgical ICUs in a medical center, Taipei Vet-
erans General Hospital, in Taiwan, from November 2010
to October 2011. Eligible patients were recruited, and
specimens of TA, BAL (see Additional file 1 for detail
methods), and serum were collected from each individual
patient on the enrollment day. BAL with or without trans-
bronchial lung biopsy (TBLB) was a routine procedure at
the discretion of the treating physicians in patients with
unrecognized pulmonary lesions in our ICU. All the speci-
mens were submitted to a bacterial culture, a fungal smear
and culture, and a BDG assay. Fungal stain was applied
routinely to inspect fungal structures microscopically.
This study was approved by the institutional review board
of Taipei Veterans General Hospital (IRB approval ID:
201011002IA) and signed informed consents were ob-
tained from all participants.
Patients
Adult, mechanically ventilated ICU patients with sus-
pected fungal pneumonia were recruited if they met all of
the following conditions: presence of appropriate host fac-
tors defined by the task force consensus (see Additional
file 1 for details about host factors) [3], non-responding or
progressive pulmonary lesions despite management with
broad-spectrum antibiotics for 48 to 72 h, and signature
on an inform consent form. Patients were excluded if they
withdrew consent, lacked respiratory specimens, had
established diagnoses other than CP, or presented with
factors that might confound the BDG assay (Fig. 1; see
Additional file 1 for details about confounding factors)
[10, 21–23]. The application of antifungal treatment
depended on the treating team, which was blinded to the
BDG results until ICU discharge. The final diagnosis was
determined by at least 2 different ICU intensivists
independently, including the primary physicians. A
conference was held to determine the final diagnosis if a
discrepancy existed.
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Diagnostic definitions
Suspected CP was defined if the cases met one of the 3
following conditions: 1) histopathological findings of poly-
morphonuclear leukocytes infiltration in lung, while the
presence of hyphae and/or pseudohyphae in the bronchial
lumen with or without peribronchial tissue invasion in
TBLB specimens; 2) TA and/or BAL cultural yield of Can-
dida spp. with successful antifungal treatment, which was
indicated by improvement in attributable symptoms and
signs, radiographic resolution of chest images, and clear-
ance of Candida spp. in repeated specimens of TA (at
least 2 times per week) or BAL (at the discretion of pri-
mary treating team); 3) TA and/or BAL-positive Candida
spp. with antifungal treatment failure, which was charac-
terized by persistent growth of Candida spp. in repeated
TA or BAL specimens in conjunction with a lack of clin-
ical and radiographic regression. For the later 2 condi-
tions, there were no other reasonably causative factors
(such as superinfection of viral or bacterial microorgan-
isms) and the treatment response was modified from the
guideline [24] recommended for invasive candidiasis other
than CP. Non-CP indicated alternative diagnoses other
than suspected CP, which included bacterial pneumonia,
viral pneumonitis, pulmonary edema or a combination of
these diseases, and all of these cases were discontinued
from antifungal treatment within 7 days. Candidemia was
defined if the blood culture was positive for Candida spp.
growth. Based on these definitions, the final diagnoses
were categorized into 3 groups: non-CP/non-candidemia,
suspected CP, and non-CP/candidemia.
Management of BDG assay
All the specimens for the BDG assay were collected and
processed within 2 h of collection, followed by frozen
storage at −70 °C until testing. The BDG assay was per-
formed (see Additional file 1 for details about methods)
using a Glucatell kit (Associates of Cape Cod, Inc.,
Falmouth, MA, USA) according to the manufacturer’s
instructions. The results of the BDG assays were not
used to categorize the final diagnosis.
Statistical analysis
Data are presented as the mean ± SD, the median with
inter-quartile range or a number (%), as appropriate.
Continuous variables were evaluated using the Kruskal-
Wallis test followed by the Mann-Whitney U test for
Fig. 1 Study algorithm. pip/taz = piperacillin/tazobactam; amo/cla = amoxicillin-clavulanate; TA = endotracheal aspirate; BAL = bronchoalveolar
lavage fluid; TBLB = transbronchial lung biopsy; PJP = Pneumocystis jiroveci pneumonia
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pairwise comparisons. Categorical data were evaluated
using the Chi-square or Fisher’s exact test. The associ-
ation between two variables was evaluated using a Pear-
son’s correlation analysis. Analyses of ROC curves were
performed to assess the predictive performance of BDG
for suspected CP or candidemia in different specimens.
The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of BDG
levels for suspected CP were also calculated, and the
best cutoff values were determined. P values <0.05 were
considered significant for all tests.
Results
Patient characteristics
After enrolling 166 consecutive patients with suspected
fungal pneumonia, 31 patients completed the study. The
final diagnoses were categorized as non-CP/non-candi-
demia (n = 18, 58.1%), suspected CP (n = 9, 29.0%), or
non-CP/candidemia (n = 4, 12.9%) (Fig. 1). In suspected
CP group, there were 4 patients with yeast in TBLB (in-
cluding one with yeast invasion in peribronchial tissue,
Fig. 2) and 5 patients judged by clinical response (3 fail-
ure and 2 success). Most of the patients’ characteristics
were similar among the study groups (Table 1). The ICU
mortality rate was 45.2% in total, but it did not signifi-
cantly differ among the study group (Table 1). There
were no independent factors to predict ICU mortality
(please see Additional file 1: Table S1). However, all sus-
pected CP cases demonstrated yeast evidence based on
TBLB histopathology and/or BAL fungal staining, and
they also had significantly higher Candida culture rates
in BAL (Table 1). Details about the cultural results for
the Candida spp. are shown in Additional file 1. All the
patients were treated with empirical antifungal agents
initially after specimen collection due to concern about
immunocompromised status and high severity scores.
BDG levels among the study groups with different
diagnoses
The mean BDG level in TA (136.6 ± 37.1 pg/ml) was
significant higher in patients with suspected CP than in
those in non-CP/non-candidemia (85.7 ± 45.1 pg/ml,
P = 0.022) and non-CP/candidemia (60.4 ± 46.6 pg/ml,
P = 0.020) (Fig. 3a). The mean BDG level in BAL was
also significantly higher in patients with suspected CP
(217.5 ± 93.4 pg/ml) than those in the non-CP/non-can-
didemia (68.8 ± 46.5 pg/ml, P < 0.001) and non-CP/can-
didemia (77.1 ± 52.2 pg/ml, P = 0.003) groups (Fig. 3b).
Conversely, the mean BDG level in serum in the non-
CP/candidemia group (221.1 ± 96.0 pg/ml) was signifi-
cantly higher than that in the non-CP/non-candidemia
group (20.1 ± 7.5 pg/ml, P < 0.001) or the suspected CP
group (22.7 ± 4.5 pg/ml, P < 0.001) (Fig. 3c).
BDG level and Candida culture results
In all the patients, the BDG level was significantly higher
in specimens with growth of Candida spp. than in those
with a negative yield in each of the 3 types of specimens
(126.2 ± 34.8 vs. 73.3 ± 47.9 pg/ml, P = 0.004 in TA;
191.0 ± 92.1 vs. 56.7 ± 30.2 pg/ml, P < 0.001 in BAL;
Fig. 2 Histological findings of transbronchial lung biopsy with Periodic Acid-Schiff stain. A representative section of necrotic tissue admixed with
inflammatory exudate showed infiltrations of acute inflammatory cells and fungus colonies in low magnification (a, 100X) as well as budding yeast
and hyphae/pseudohyphae appearance in high magnification (b, 400X). Sections of peribronchial tissue disclosed epithelial sloughing with yeast
invasion in bronchial mucosa (c, 400X) and bronchial cartilage (d, 400X)
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221.1 ± 96.0 vs. 21.0 ± 6.7 pg/ml, P = 0.001 in serum)
(Fig. 4a). Additionally, the value of TA BDG was positively
correlated with that of BAL BDG (P = 0.002, r = 0.542)
(Fig. 4b). However, the value of neither TA BDG
(P = 0.598; r = 0.098) nor BAL BDG (P = 0.836; r = 0.039)
was significantly correlated with that of serum BDG.
Diagnostic value of BDG in detecting suspected CP
For the detection of suspected CP, measuring BDG levels
in both TA and BAL, but not the serum BDG level, could
have good diagnostic value. The results from the ROC
analysis revealed that BDG levels in TA and BAL had
AUROC values of 0.833 and 0.939, respectively (Fig. 5).
Given a cutoff BDG level of 120 pg/ml in TA and 130 pg/
ml in BAL, the best diagnostic value could be achieved
with sensitivity/specificity of 67%/82% for TA and 89%/
86% for BAL (Table 2). The serum BDG level exerted ex-
cellent predictive performance for the detection of candi-
demia (AUROC =0.996, P = 0.001) but poor predictive
performance for the detection of suspected CP (AUROC
=0.510, P = 0.931, Fig. 5). In addition, measuring the BDG
level in TA (AUROC =0.259, P = 0.126) or BAL (AUROC
=0.389, P = 0.480) for the detection of candidemia was of
no diagnostic value.
Table 1 Patients’ characteristics
All Non-CP/non- candidemia Suspected CP Non-CP/ candidemia P
Number 31 18 9 4
Age, year 66.4 ± 16.6 65.3 ± 18.5 66.9 ± 16.5 70.3 ± 6.2 0.971a
Sex, male (%) 20 (64.5) 11 (61.1) 6 (66.7) 3 (75.0) 0.860b
APACHE II at ICU admission 22.4 ± 5.2 22.3 ± 5.2 21.1 ± 4.2 25.3 ± 6.9 0.583a
APACHE II on enrolled day 24.2 ± 4.8 23.2 ± 5.0 25.1 ± 3.9 27.0 ± 5.3 0.316a
Initial reasons for MV (%)
Post-surgery 7 (22.6%) 3 (16.7) 2 (22.2) 2 (50.0) 0.353b
Pneumonia 24 (77.4%) 15 (83.3) 7 (77.8) 2 (50.0) 0.353b
Reasons for BAL (%)
Non-responding pneumonia 18 (58.1) 9 (50.0) 7 (77.8) 2 (50) 0.363b
Newly developed infiltration 13 (41.9) 9 (50.0) 2 (22.2) 2 (50) 0.363b
Host factors (%)
Recent neutropenia 10 (32.3) 5 (27.8) 2 (22.2) 3 (75.0) 0.141b
Prolonged steroid use 16 (51.6) 10 (55.6) 5 (55.6) 1 (25.0) 0.521b
Immunosuppressants 5 (16.1) 3 (16.7) 2 (22.2) 0 0.600b
MV days 24.2 ± 12.5 23.7 ± 14.9 22.9 ± 9.4 29.3 ± 5.7 0.129a
ICU stay, days 27.8 ± 11.9 28.0 ± 14.4 26.6 ± 9.2 30.0 ± 4.3 0.494a
ICU mortality (%) 14 (45.2) 6 (33.3) 5 (55.6) 3 (75.0) 0.241b
Radiographic manifestationsc (%)
Halo sign 1 (3.2) 0 1 (11.1) 0 0.283b
Single/multiple nodules 11 (35.5) 3 (16.7) 7 (77.8) 1 (25.0) 0.007b
Cavitary lesion 6 (19.4) 3 (16.7) 3 (33.3) 0 0.338b
GGO/infiltration 29 (93.5) 17 (94.4) 8 (88.9) 4 (100) 0.732b
Mycological evidence of yeast (%)
TBLBd,e 4 (12.9) 0 4 (44.5) 0 < 0.001b
BALe 13 (41.9) 4 (22.2) 8 (88.9) 1 (25.0) 0.003b
TA fungal culture 14 (45.2) 7 (38.9) 6 (66.7) 1 (25.0) 0.269b
BAL fungal culture 13 (41.9) 5 (27.8) 8 (88.9) 0 0.002b
Data are presented with means ± standard deviations
CP Candida pneumonia, APACHE acute physiology and chronic health evaluation, MV mechanical ventilation, BAL bronchoalveolar lavage, GGO ground glass
opacity, TBLB transbronchial lung biopsy, TA endotracheal aspirate, BAL bronchoalveolar lavage fluid
aKruskal-Wallis test
bFisher’s exact test
cEach single patient could have more than one type of radiographic manifestation
dA total of 19 patients underwent TBLB, including 11 in non-CP/non-candidemia, 7 in suspected CP, and 1 in non-CP/candidemia
eFungal staining was applied using Grocott-Gomori methenamine silver stain in BAL and Periodic Acid-Schiff stain in TBLB
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Discussion
To our knowledge, the present study was the first to com-
pare the diagnostic value of measuring BDG levels in TA,
BAL, and serum for the detection of suspected CP in im-
munocompromised and critically ill patients. The major
findings were that measuring BDG levels in respiratory
specimens, including both TA and BAL fluid, exerted
good diagnostic value for the detection of suspected CP,
particularly in the absence of concurrent candidemia. In
contrast, measuring the serum BDG level had no diagnos-
tic value for this detection.
There are limited data regarding measuring BAL BDG
levels to diagnose fungal pneumonia. The performance of
BAL BDG at different cutoff value to diagnose non-Can-
dida fungal pneumonia varied widely, in terms of sensitivity
(53-90%) and specificity (26-88%) in different patient popu-
lations [25–28]. Among these, the largest study (268 BALs)
reported by Prattes et al., who compared BAL galactoman-
nan and BDG to diagnose proven/probable invasive pul-
monary aspergillosis. They concluded that despite similar
sensitivity (> 90%) and NPV (> 90%) between galactoman-
nan and BDG, BAL BDG was less convincing due to low
specificity (< 50%). This might be ascribed to frequent re-
spiratory colonization of Candida spp. [28], which poten-
tially limited the diagnostic performance of BAL BDG for
non-Candida fungal pneumonia. In contrast, we excluded
most of the possible confounding factors and focused on
Candida pathogens. Thus, our data showed good perform-
ance (both sensitivity and specificity >85%) by means of
measuring BAL BDG. Moreover, consistent with the obser-
vation reported by Reischies et al. [29], our data also
showed that Candida culture-positive specimens had
higher BDG levels (Fig. 4a), which implicates that BDG
levels reflect fungal burdens indirectly. Patients with higher
fungal burdens are more susceptible to fungal infection.
This potentially provide the rationale to measure respiratory
BDG levels as good diagnostic aid to detect suspected CP.
We further showed that the TA BDG level was positively
correlated with BAL BDG (Fig. 4b). Despite with inferior
value to BAL BDG, measuring TA BDG also offered good
diagnostic performance for the detection of suspected CP
(Fig. 5). Thus, measuring TA BDG could serve as a simple,
less-invasive, alternative diagnostic for suspected CP when
BAL is unavailable. Previously, most cases of CP were
considered to indicate lung involvement of disseminated
candidiasis rather than primary CP [1, 5]. Based on this
belief, patients with CP are supposed to have as high of a
serum BDG level as those with candidemia. However, our
data did not correspond to this notion. Patients with sus-
pected CP had apparently low BDG in serum (vs. those
with non-CP/candidemia) and high BDG in TA and BAL
(Fig. 3). These findings suggested that serum BDG might
have no diagnostic value in patients with suspected CP in
the absence of concurrent candidemia. Thus, we suggest
clinicians should directly measure BDG in respiratory
specimens in patients with suspicion of CP.
To date, there have been no universally acceptable cri-
teria to diagnose CP, and most diagnoses have depended
on lung biopsies. CP is considered uncommon based on
earlier lung autopsy reports [1, 6, 8], so the clinical prac-
tice guideline does not recommend using antifungal treat-
ment based upon the Candida culture alone [3, 5, 30].
Fig. 3 The levels of (1,3)-β-D-glucan (BDG) in specimens of endotracheal
aspirate (a, TA), bronchoalveolar lavage fluid (b, BAL), and serum (c),
categorized by different diagnoses. CP = Candida pneumonia. The
shallow cycle indicates overlap of 2 outliers (180.8 and 178.0 pg/ml).
*P < 0.05; **P < 0.01, ***P < 0.001. Statistical evaluations were performed
using the Kruskal-Wallis test followed by the Mann-Whitney U test
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However, CP might possibly be under-diagnosed in critic-
ally ill patients because a lung biopsy is rarely performed.
Indeed, even for immunocompetent ICU patients with
Candida-positive respiratory specimens, 24.2% of physi-
cians recommended antifungal treatment in an early ques-
tionnaire surveillance regarding CP [31] and 32.9% did so
in a recent prospective study concerning ICU-acquired
pneumonia [32]. These reports reflected the dissociation
of managements between the guideline [3, 5, 30] and real-
life ICU situations remain an unresolved issue. It is logic-
ally speculated that antifungal treatment are more fre-
quently used for immunocompromised and critically ill
ICU patients, particularly while these patients were under-
going non-responding or progressive pneumonia with the
presence of respiratory Candida spp. and the absence of
the other causative pathogens after thorough work-ups.
Thus, applying antifungal treatment response in these sit-
uations might be reasonably therapeutic diagnostics for
suspected CP and could compensate the gap between the
Fig. 4 a BDG levels categorized by fungal cultural results in different types of specimens. **P < 0.01, ***P < 0.001. TA = endotracheal aspirate;
BAL = bronchoalveolar lavage fluid. b Binary correlation of values of TA BDG and BAL BDG. r = correlation coefficient. Statistical evaluations were
performed using the Mann-Whitney U test in A and using Pearson’s correlation coefficient in b
Fig. 5 The receiver operating characteristic curve of BDG levels in
different types of specimens for the diagnosis of suspected Candida
pneumonia (CP). TA = endotracheal aspirate; BAL = bronchoalveolar
lavage fluid; AUC = area under the curve; CI = conference interval
Table 2 Predictive performance of various BDG levels for
diagnosing candidemia and suspected CP in different
specimens
Cutoff value Sensitivity Specificity PPV NPV
Candidemia
Serum BDG, pg/ml
70 100% 100% 100% 100%
80 100% 100% 100% 100%
90 75% 100% 100% 96%
Suspected CP
TA BDG, pg/mla
90 89% 55% 44% 92%
100 89% 59% 47% 93%
110 78% 68% 50% 88%
120 67% 82% 60% 86%
130 0% 70% 0% 83%
BAL BDG, pg/ml
110 89% 73% 57% 94%
120 89% 77% 62% 94%
130 89% 86% 73% 95%
140 89% 91% 80% 95%
150 67% 91% 75% 95%
Serum BDG, pg/ml
20 67% 41% 32% 75%
25 33% 59% 25% 68%
30 0% 73% 0% 64%
PPV positive predictive value, NPV negative predictive value, BDG β-D-glucan
Refer to Table 1 for other abbreviations
aAdjusted to per gram of endotracheal aspirate
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guideline and clinical scenario. Accordingly, more prac-
tical diagnostic criteria for detecting suspected CP are ur-
gently needed. Our findings showed measuring respiratory
BDG levels might provide valuable information to en-
hance these diagnostic criteria.
There were some limitations of our study. First, our
data were derived from selected patients to minimize
confounding factors. Particularly, we excluded many pa-
tients with concurrent use of antibiotics. The concern
that if concurrent use of antibiotics possibly confounded
BDG assay remains a conflicting issue [33–40]. It needs
a large-scale study to validate this issue. Second, the
sample size of this study was small, and future investiga-
tions with larger sample sizes will be needed to optimize
the best TA or BAL BDG cutoff values. Third, our re-
sults were derived from the study of Candida spp.; the
application of measuring BDG levels in other fungal
pathogens requires further validation.
Conclusions
This study is not intended to replace lung biopsy for the
diagnosis of CP, but try to use less invasive biomarker to de-
tect suspected CP. Our results clearly showed that the BDG
level in BAL or TA provided a good diagnostic value to de-
tect suspected CP. Additionally, measuring serum BDG
had no diagnostic value for detecting suspected CP in the
absence of concurrent candidemia. These findings warrant
a future large-scale investigation to validate the optimal cut-
off value for BDG in respiratory specimens and to deter-
mine the timing to initiate antifungal treatment.
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